drugset / Trial / NCT02797717
Treatment for Classical Hodgkin Lymphoma in Children and Adolescents
RandomizedParallel-groupOpen-labelTreatment
Summary
Reduction of the indication for radiotherapy (RT) in newly diagnosed patients with classical Hodgkins lymphoma without compromising cure rates. Investigation of a chemotherapy intensification randomisation in intermediate and advanced classical Hodgkins lymphoma patients to compensate for reduction in RT.
Timeline
- Start
- 2015-11
- Primary completion
- 2022-12
- Completion
- 2027-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Cyclophosphamide | Other / unclassified | 500 mg/m2 | Intravenous |
| Subject | Cyclophosphamide | Other / unclassified | 625 mg/m2 | Intravenous |
| Subject | Doxorubicin | Other / unclassified | 25 mg/m2 | Other |
| Subject | Etoposide | Small molecule | 100 mg/m2 | Other |
| Background | Dacarbazine | Small molecule | 250 mg/m2 | Intravenous |
| Background | Prednisone | Other / unclassified | 40 mg/m2 | Oral |
| Background | Vincristine | Small molecule | 15 mg/m2 | Intravenous |